Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan spars with agency over status of US manufacturing probe

This article was originally published in Scrip

Executive Summary

Mylan Laboratories held firm its view during its second-quarter earnings conference call that recent allegations of misconduct at its West Virginia manufacturing plant put forward in a news story in the Pittsburgh Post-Gazette are unfounded and that an FDA probe into possible problems at the plant had been closed, with no further issues. Statements by the agency have conflicted with that view, causing volatility in Mylan's share price.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts